Related references
Note: Only part of the references are listed.Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach
Yacine Bareche et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses
Caterina Fumagalli et al.
BREAST CANCER RESEARCH (2020)
Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy
Changlong Liu et al.
CANCER RESEARCH (2019)
Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge
Milica Nedeljkovic et al.
CELLS (2019)
A Novel Cell-Penetrating Antibody Fragment Inhibits the DNA Repair Protein RAD51
Landon Pastushok et al.
SCIENTIFIC REPORTS (2019)
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
Y. Bareche et al.
ANNALS OF ONCOLOGY (2018)
Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing
Charissa Kim et al.
CELL (2018)
The Crystal Structure of the R280K Mutant of Human p53 Explains the Loss of DNA Binding
Ana Sara Gomes et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt et al.
NATURE MEDICINE (2018)
Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells
Amila K. Nanayakkara et al.
SCIENTIFIC REPORTS (2018)
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Marta Castroviejo-Bermejo et al.
EMBO MOLECULAR MEDICINE (2018)
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer
Melinda L. Telli et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma
Lawrence N. Kwong et al.
CELL REPORTS (2017)
The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer
Brock J. Sishc et al.
CANCERS (2017)
Quinazolinone derivatives as inhibitors of homologous recombinase RAD51
Ambber Ward et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells
Stine Ninel Hansen et al.
BMC GENOMICS (2016)
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
Suzanne Leijen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
New insight on the biological role of p53 protein as a tumor suppressor: re-evaluation of its clinical significance in triple-negative breast cancer
Min-Sun Jin et al.
TUMOR BIOLOGY (2016)
Negative Selection and Chromosome Instability Induced by Mad2 Overexpression Delay Breast Cancer but Facilitate Oncogene-Independent Outgrowth
Konstantina Rowald et al.
CELL REPORTS (2016)
Targeting DNA Replication Stress for Cancer Therapy
Jun Zhang et al.
GENES (2016)
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants
Fresia Pareja et al.
NPJ BREAST CANCER (2016)
Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51
Ambber Ward et al.
CANCER TREATMENT REVIEWS (2015)
Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution
Hoon Kim et al.
GENOME RESEARCH (2015)
Targeting the DNA Damage Response in Cancer
Mark J. O'Connor
MOLECULAR CELL (2015)
A Critical Dose of Doxorubicin Is Required to Alter the Gene Expression Profiles in MCF-7 Cells Acquiring Multidrug Resistance
Shang-Hsun Tsou et al.
PLOS ONE (2015)
Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment
Bernard Leroy et al.
HUMAN MUTATION (2014)
Mechanisms underlying mutational signatures in human cancers
Thomas Helleday et al.
NATURE REVIEWS GENETICS (2014)
Genome-wide transcriptome profiling of homologous recombination DNA repair
Guang Peng et al.
NATURE COMMUNICATIONS (2014)
Rad51 supports triple negative breast cancer metastasis
Adrian P. Wiegmans et al.
ONCOTARGET (2014)
Mechanisms, function and clinical applications of DNp73
Cuixia Di et al.
CELL CYCLE (2013)
Mutant p53-Notch1 Signaling Axis Is Involved in Curcumin-Induced Apoptosis of Breast Cancer Cells
Yun-Hee Bae et al.
KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY (2013)
A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer
Christos Hatzis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Overexpression of RAD51 occurs in aggressive prostatic cancer
Anita Mitra et al.
HISTOPATHOLOGY (2009)
ATR: an essential regulator of genome integrity
Karlene A. Cimprich et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
A chemical compound that stimulates the human homologous recombination protein RAD51
Krishanthi Jayathilaka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
DNA repair pathways as targets for cancer therapy
Thomas Helleday et al.
NATURE REVIEWS CANCER (2008)
RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors
Richard W. Martin et al.
CANCER RESEARCH (2007)
The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy
B. Salles et al.
PATHOLOGIE BIOLOGIE (2006)
P53 modulates homologous recombination by transcriptional regulation of the RAD51 gene
C Arias-Lopez et al.
EMBO REPORTS (2006)
Mechanism and regulation of human non-homologous DNA end-joining
MR Lieber et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis
D Bergamaschi et al.
CANCER CELL (2003)
Share Paper
